相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
Giacomo Bregni et al.
JAMA ONCOLOGY (2019)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
ONCOLOGIST (2019)
Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Kanwal Raghav et al.
JCO PRECISION ONCOLOGY (2019)
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients
Zhu Mei et al.
BMC CANCER (2018)
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios
Nicola Normanno et al.
CANCER TREATMENT REVIEWS (2018)
FBXW7: a critical tumor suppressor of human cancers
Chien-Hung Yeh et al.
MOLECULAR CANCER (2018)
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Khurum H. Khan et al.
CANCER DISCOVERY (2018)
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Anita Sveen et al.
CLINICAL CANCER RESEARCH (2018)
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
N. Normanno et al.
ANNALS OF ONCOLOGY (2018)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
Krittiya Korphaisarn et al.
ONCOTARGET (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
C. Cremolini et al.
ANNALS OF ONCOLOGY (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody
Daniela Adua et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
How the lab is changing our view of colorectal cancer
Chiara Cremolini et al.
TUMORI JOURNAL (2016)
How the lab is changing our view of colorectal cancer
Chiara Cremolini et al.
TUMORI JOURNAL (2016)
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
N. Normanno et al.
ANNALS OF ONCOLOGY (2015)
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
Laura Lupini et al.
BMC CANCER (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
First-line chemotherapy for mCRC-a review and evidence-based algorithm
Chiara Cremolini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurent-Puig et al.
CLINICAL CANCER RESEARCH (2015)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2014)
Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Justin Guinney et al.
CLINICAL CANCER RESEARCH (2014)
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Elza C. de Bruin et al.
CANCER DISCOVERY (2014)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
Inhibitory role of Gas6 in intestinal tumorigenesis
Reiko Akitake-Kawano et al.
CARCINOGENESIS (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma
Jenifer L. Marks et al.
CANCER RESEARCH (2008)
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression
Jian-Hua Mao et al.
SCIENCE (2008)
分享论文
